Latest News for: alk

Edit

Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia

PR Newswire 01 Apr 2025
ALKS) today announced the initiation of Vibrance-3, a phase 2 clinical study evaluating the safety and efficacy of ALKS 2680 compared to placebo in adults with idiopathic hypersomnia (IH). ALKS 2680 is ...
Edit

Annual General Meeting 2025 Minutes (ALK-Abelló A/S)

Public Technologies 27 Mar 2025
Minutes of the Annual General Meeting of ALK-Abelló A/S ... ALK-Abelló A/S ... (the "company" or "ALK") ... ALK's business ... 2024 was a good and rewarding year for ALK ... ALK has to grow profitably! ... Important steps for ALK.
Edit

Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor, Neladalkib, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2025

PR Newswire 25 Mar 2025
Mutagenesis screens support potential best-in-class profile for neladalkib (NVL-655), a brain-penetrant and TRK-sparing ALK inhibitorAuthors ... observed with currently available ALK inhibitors.
  • 1
×